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Alkaptonuria (AKU) is an ultra-rare genetic disease, in which the accumulation of a toxic 
metabolite, homogentisic acid (HGA) leads to the systemic development of ochronotic aggregates. 
These aggregates cause severe complications mainly at the level of joints with extensive 
degradation of the articular cartilage. Primary cilia have been demonstrated to play an essential role 
in development and the maintenance of articular cartilage homeostasis, through their involvement in 
mechanosignalling and Hedgehog signalling pathways. Hedgehog signalling has been demonstrated 
to be activated in osteoarthritis (OA) and to drive cartilage degeneration in vivo. The numerous 
similarities between OA and AKU suggest that primary cilia hedgehog signalling may also be 
altered in AKU.  
Thus, we characterised an AKU cellular model in which healthy chondrocytes were treated with 
HGA (66 μM) to replicate AKU cartilage pathology. We investigated the degree of activation of the 
hedgehog signalling pathway and how treatment with inhibitors of the receptor Smoothened (Smo) 
influenced hedgehog activation and primary cilia structure. The results obtained in this work 
provide a further step in the comprehension of the pathophysiological features of AKU, suggesting 
a potential therapeutic approach to modulate AKU cartilage degradation processes through 
manipulation of the hedgehog pathway.  
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Alkaptonuria (AKU) is an ultra-rare genetic metabolic disease (1:250.000 - 1.000.000), in which 
mutations of the enzyme homogentisate 1,2 dioxygenase (HGD) prevent it from metabolizing 
homogentisic acid (HGA) in the catabolic pathway of tyrosine and phenylalanine (Braconi et al., 
2015). Accumulation of this toxic compound and its derivatives results in urine darkening and in 
the formation of pigmented protein aggregates causing ochronosis within the whole organism. For 
this reason, AKU is considered a multi-systemic disease, although the most common body districts 
severely affected by HGA accumulation are joints, as AKU patients evidence serious movement 
impairments resulting in an ochronotic arthropathy. There are numerous findings indicating that, 
among the processes that lead to cartilage degradation in AKU, important roles are played by 
oxidative stress (Braconi et al., 2011; Braconi et al., 2010; Braconi et al., 2015), inflammation 
(Millucci et al., 2014c), and accumulation of serum amyloid A (SAA), describing AKU as a 
secondary amyloidosis (Millucci et al., 2015a; Millucci et al., 2014a; Millucci et al., 2014b). More 
recently, the structural analysis of AKU chondrocyte cytoskeleton revealed that the organization of 
the three main cytoskeletal proteins (tubulin, actin and vimentin) is altered in AKU cells (Geminiani 
et al., 2016) and that chondrocytes cultured in HGA-added medium started developing the same 
alterations observed in AKU chondrocytes. Alterations in cytoskeletal tension have previously been 
shown to regulate the structure and function of primary cilia (McMurray et al., 2013; Pitaval et al., 
2010). Primary cilia are signalling organelles involved in numerous signalling pathways (for review 
see (Berbari et al., 2009). In articular cartilage primary cilia mediate mechanosignalling (Wann et 
al., 2012), inflammatory signalling (Wann et al., 2014; Wann and Knight, 2012; Wann et al., 2013) 
and Hedgehog (Hh) signalling (Thompson et al., 2014; Thompson et al., 2016). All have been 
linked to osteoarthritis, however this study concentrates on whether Hh signalling is disrupted in a 
cellular model of AKU. Briefly, hedgehog signalling is activated by the binding of one of the three 
Hh ligands (Sonic Hedgehog, Shh; Indian Hedgehog, Ihh; Desert Hedgehog, Dhh) to the receptor 
located on the cellular membrane, Patched 1 (Patch-1). This enables the trafficking and localization 
on the primary cilium of a seven-transmembrane-span receptor-like protein, Smoothened (Smo) 
(Ingham and McMahon, 2001). This then leads to the activation of the transcriptional activators, 
Gli-1 and Gli-2, and suppression of the transcriptional repressor, Gli-3. Studies from Knight’s 
group have shown that Hh signalling is modulated by changes in primary cilia length induced by 
mechanical loading (Thompson et al., 2014) or lithium chloride (Thompson et al., 2016). 
A relationship between the activation of the Hh pathway and osteoarthritis (OA) has previously 
been described in vivo (Akhtar et al., 2015; Lin et al., 2009; Wei et al., 2012) although other in vitro 
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studies show that Hh signalling alone does not directly activate cartilage degradation (Thompson et 
al., 2015). Hh signalling is also implicated in the regulation of chondrocytes growth and 
differentiation (St-Jacques et al., 1999). The numerous similarities between AKU and OA 
pathogenesis prompted us to investigate the effects of Hh signalling pathway modulation in AKU. 
In the present study we therefore investigated the potential to regulate hedgehog signalling in 
healthy and HGA-treated human chondrocytes. For these studies we used four Smo-antagonists, 
namely cyclopamine, vismodegib and two other recently described antagonists, MRT89 and 
MRT61 (Hoch et al., 2015; Solinas et al., 2012). We measured the response in terms of the 
expression of the constitutive activator of Hh signalling, Gli-1 and the length of the primary cilia. 
The aim of this study was therefore to examine primary cilia length in articular chondrocytes 
isolated from AKU patients and to set-up an AKU cell model in order to analyse the activation of 
the Hh signalling pathway and its inhibition by means of specific antagonists of the receptor Smo. 
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Materials and methods 
Anti-Smo compounds 
The Smo agonist SAG was purchased from Cayman Chemical (Michigan, USA), vismodegib from 
Santa Cruz Biotechnology (Dallas, Texas, USA) and cyclopamine, MRT89 and MRT61 were 
synthesized in our laboratories as previously reported by us (Hoch et al., 2015; Manetti et al., 2010; 
Roudaut et al., 2011; Solinas et al., 2012). These compounds were selected from among a small 
library of available compounds, on the basis of previous experiments in which their inhibition 
activity against Smo was determined (data not shown). All the testing compounds are listed in 
Table 1SM.  
Chondrocyte isolation, culture and treatment 
Primary human articular chondrocytes were isolated from articular cartilage samples by means of 
enzymatic extraction, as previously described (Braconi et al., 2012). All the samples were obtained 
from consenting AKU patients or patients not affected from rheumatic pathologies following 
traumatic accident surgeries. The experiments performed in this study were conducted according to 
the principles of the Declaration of Helsinki (64
th
, 2013) and received approval from the Local 
Ethics Committee.  
Primary human articular chondrocytes were cultured in high glucose Dulbecco’s modified Eagle 
Medium (DMEM), 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (P/S) at 37 °C, 
5% CO2. To reproduce in vitro the phenotypic and structural features of AKU chondrocytes, 
healthy chondrocytes were treated for two weeks with 66 µM HGA (Sigma Aldrich, St Louis, MO).  
Upon reaching confluence, cells were serum-starved (0.5% FBS) for 24 h before treatments with 
SAG and/or Smo antagonists cyclopamine, vismodegib, MRT89 and MRT61. 
For immunofluorescence analysis, chondrocytes were seeded onto coverslips in 24 well plates and, 
after serum starvation, were treated with Smo antagonists (1, 10 and 100 nM) for 24 h. For Western 
blot analysis, cells were incubated with Smo antagonists (1, 10, 100 nM) in addition to 100 nM 
SAG, in order to ensure Hh signalling pathway activation. 
Immunofluorescence and confocal microscopy 
For immunofluorescence analysis of primary cilia, confluent chondrocytes were fixed with 4% PFA 
for 10 min, permeabilized with 0.5% Triton-X-100 and incubated for 45 min in the blocking 
solution (5% goat serum). For detection of primary cilia, mouse anti-acetylated tubulin, clone 6-
11B-1 (1:1000, Sigma Aldrich) was used, by incubating coverslips at 4 °C overnight. After repeated 
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washing in 0.1% bovine serum albumin (BSA)/phosphate buffered saline (PBS), cells were 
incubated with an anti-mouse, Alexa Fluor-conjugated secondary antibody (1:1000, Life 
Technologies, California, USA) for 1 h at room temperature (rt). DAPI (4',6-diamidino-2-
phenylindole) staining was used for nuclei detection (1 µg/mL, Sigma Aldrich). Following 
washings in 0.1% BSA/PBS, coverslips were mounted with Fluoromount G (Southern Biotech, 
Alabama, USA).  
Imaging and quantification of cilia length was performed on a Leica TCS SP5 AOBS confocal 
microscope with a x63/1.4-NA lens. Sequential z-stacked sections were imaged through the entirety 
of the cellular profile using Z-step size of 0.5 µm, 2x or 4x zoom and an image format of 1024 x 
1024 pixels. Z stacks were reconstructed and 2D maximum intensity projections (MIPs) were 
created in order to measure cilia length by means of the software Image J. Approximately 100 cilia 
were measured over five representative fields of view for each experimental condition. 
Viability assay  
To assess whether treatment with anti-Smo compounds affected cells viability, MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was performed. 80% confluent cells 
were incubated for 3 h with 1 mg/mL MTT (Sigma Aldrich). Resulting formazan crystals were 
dissolved with DMSO and samples were read spectrophotometrically at 550 nm. 
Western blot analysis  
Protein lysates were obtained firstly by lysing cells in RIPA buffer (1% Triton-X100, 100 mM 
NaCl, 0.1% SDS, 50 mM Tris pH 7.2), containing Na3VO4 and a protease inhibitor cocktail (Sigma 
Aldrich), and then by sonication. Protein extracts were quantified by BCA protein assay according 
to the manufacturer’s instructions (Thermo Fisher Scientific, Massachusetts, USA). Proteins from 
healthy and HGA-treated chondrocytes were separated by SDS-PAGE, loading 40 µg of total 
protein lysate on 8% acrylamide gel. Proteins were electro-transferred onto nitrocellulose 
membrane (0.45 mm pore size; Whatman, Maidstone, UK), blocked for 1 h at rt in 5% BSA in 
0.05% Tween-20 phosphate buffered saline (PBS-T) and then incubated with anti-Gli-1 primary 
antibody (1:200, Santa Cruz Biotechnology) at 4 °C overnight. Membranes were washed in PBS-T 
and then incubated with appropriate HRP-conjugated secondary antibody (1:5000, GE Healthcare, 
Little Chalfont, UK) for 1 h at rt. For GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 
detection, membranes were incubated with anti-GAPDH antibody (1:50000, Abcam, Cambdridge, 
UK) for 3 h at rt. After three washings in PBS-T, membranes were visualized using Luminata 
Crescendo (Millipore, Italy) and images acquired using ImageQuant LAS4000 (GE Healthcare). 
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Analysis of band intensities was performed by ImageQuant TM TL analysis software (GE 
Healthcare).  
Statistical analysis 
All statistical analyses were conducted using Graph Pad Prism 6.01. Data were analysed by one-
way or two-way ANOVA with post hoc Tukeys's multiple comparisons. Data is presented as mean 
± S.E.M. resulting from three independent experiments and in all cases statistically significant 
differences in relation to the untreated control were indicated at p < 0.05 (*), p < 0.01 (**), p < 
0.001 (***) and p < 0.0001 (****).  
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HGA-induced pigmentation validated the AKU cell model  
In order to reproduce in vitro the phenotypic characteristics of AKU chondrocytes, healthy 
chondrocytes were maintained in culture for 14 days in a medium containing 66 µM HGA. Phase 
contrast images evidenced that healthy chondrocytes appeared transparent (Figure 1A), while AKU 
chondrocytes exhibited a black pigmentation, mainly localized around the nuclei (Figure 1B). The 
same features were observed in cells cultured in presence of HGA (Figure 1C), with a lower 
pigment deposition prevalence in respect to AKU cells.  
AKU and HGA-treated chondrocytes exhibited shorter primary cilia and altered Hh 
signalling 
Primary cilia were visualised by immunofluorescence in healthy, AKU and HGA-treated 
chondrocytes by labelling with anti-acetylated α-tubulin antibodies (Figure 2A). In healthy human 
chondrocytes the cilia length was 3.6 ± 1.7 µm (mean ± SEM). Cilia length was reduced in AKU 
(2.5 ± 1 µm) and HGA-treated chondrocytes (2.7 ± 1 µm) and the differences were statistically 
significant (Figure 2B). These studies further support the suitability of HGA treatment as a model 
of AKU.  
Western blot analysis of Gli-1 expression in the three cell groups (Figure 2C) demonstrated that Hh 
signalling was altered in AKU and HGA-treated cells. In particular, Gli-1 protein was expressed at 
higher levels in the disease condition (AKU and +HGA), in respect to healthy chondrocytes.  
Anti-Smo treatment did not affect cell viability  
Cell viability after a 24 h treatment with Smo antagonists was assessed by means of MTT assay. 
DMSO was used as control substance, since it was the dissolving agent for all the test compounds. 
Absorbance values at 550 nm were registered and results were normalised to the untreated value 
and given as a percentage. HGA or DMSO treatment had no statistically significant effect on cell 
viability compared to untreated controls (Figure 3). The assay allowed evaluation of the 
cytotoxicity of the antagonists of Smo in presence of HGA. Cell viability was not significantly 
altered after treatment with any of the four testing Smo antagonists at concentrations of 1-100 nM.  
Primary cilia elongated following anti-Smo treatments 
Immunofluorescence assay was performed on primary human chondrocytes cultured onto 
coverslips and treated for 24 h with anti-Smo compounds at three different concentrations (1, 10 
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and 100 nM), in the presence of 66 µM HGA. Confocal imaging and cilia length measurement 
revealed that after treatment with Smo antagonists primary cilia lengths assumed values comparable 
to that of normal cells in a concentration-dependent manner (Figure 4). Table 1 shows the mean ± 
S.E.M cilia length and the percentage difference calculated in respect to HGA-treated cells in the 
absence of any Smo antagonist. The greatest cilia lengths values were obtained after treatment with 
either cyclopamine or vismodegib at 100 nM. In the presence of HGA, treatment with these Smo 
antagonists, even at lower concentration of 1 and 10 nM, was sufficient to restore the primary cilia 
to lengths seen in normal cells such that there were no statistically significant differences. 
Chondrocytes treated with MRT89 and MRT61 also showed primary cilia close to lengths values 
calculated in control cells, at 100 nM. In particular, MRT89 appeared to be more effective than 
MRT61 in restoring cilia length. 
Anti-Smo treatment reduced Hedgehog signalling activation 
The expression of Gli-1 protein was evaluated in order to quantify the activation of the Hh 
signalling pathway in our treated and untreated cell groups. In all cases, the pathway was stimulated 
by the agonist SAG (100 nM) to amplify the level of expression of the protein. By means of western 
blot analysis, Gli-1 expression was higher in HGA-treated chondrocytes compared to healthy cells 
and decreased following a 24 h treatment with anti-Smo compounds (Figure 5A). Band 
quantification confirmed that the differences were statistically significant in a concentration-
dependent manner and that in all cases it was possible to restore the expression of Gli-1 to the 
normal levels (Figure 5B). In particular, cyclopamine, vismodegib and the analogue MRT61 were 
also found to be effective at the lowest concentrations (1 and 10 nM).  
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AKU replicates aspects of joint pathology seen in more common rheumatic diseases, such as OA 
and rheumatoid arthritis (Tinti et al., 2010a). Degeneration of articular cartilage, loss of joint 
function, synovial inflammation, sub-chondral bone thickening, osteophyte formation, degeneration 
of ligaments in the knee and menisci, as well as chondroptosis, a peculiar type of cell death 
observed in cartilage, are features shared between OA and AKU (Millucci et al., 2015b).  
Although AKU is a well-described condition from a clinical point of view, the molecular bases of 
the disease are still quite obscure. In particular, the difficulty of collecting ochronotic samples, 
which require very invasive techniques, together with the fact that ochronosis often causes severe 
damage to tissues, make the collection of suitable samples from biopsies more problematic. 
Consequently, the difficulty to obtain human samples for experimental studies has led to the 
necessity to design alternative methods to study AKU pathophysiology. Numerous findings 
evidence that the toxic metabolite HGA is the main responsible of the physio-pathological features 
of AKU (Geminiani et al., 2016; Millucci et al., 2015b; Tinti et al., 2010b), since it accumulates 
systematically generating ochronotic aggregates together with amyloid deposits (Millucci et al., 
2014c). In this work, we demonstrated that, by adding a 66 µM solution of HGA to the culture 
medium of primary isolated human chondrocytes, a black pigmentation was visible within cells by 
phase contrast imaging, entirely reproducing the phenotype of alkaptonuric chondrocytes. A further 
confirmation that HGA is responsible for the pathologic phenotype of AKU chondrocytes derived 
from the immunofluorescent assay of primary cilia in the three cellular groups analysed. Acetylated 
α-tubulin staining revealed that primary cilia were shorter in AKU and HGA-treated chondrocytes 
in agreement with recent findings on cytoskeleton alterations in AKU. We have recently 
demonstrated that the cytoskeleton markers β-tubulin, actin and vimentin were severely altered in 
AKU chondrocytes and that HGA treatment reproduced the same ochronotic phenotype in healthy 
cells (Geminiani et al., 2016). These findings have prompted further investigation into AKU 
associated changes in the cytoskeletal structure known as the primary cilium and the functional 
implications. Numerous experimental results demonstrated that this organelle is fundamental for 
several cellular processes (Berbari et al., 2009; Ruhlen and Marberry, 2014) and that in cartilage it 
has a fundamental role in mechanosignalling (Wann et al., 2012), inflammatory signalling (Wann et 
al., 2014; Wann and Knight, 2012; Wann et al., 2013) and hedgehog signalling (Haycraft and Serra, 
2008; Thompson et al., 2014; Thompson et al., 2016).  
Hedgehog signalling has an important role in skeleton development (Yang et al., 2015) and acts to 
regulate cell differentiation, proliferation and survival in many developmental processes (Day and 
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Yang, 2008). Previous studies on osteoarthritic cartilage showed that Hh signalling is activated in 
OA and promotes cartilage degeneration (Lin et al., 2009; Tchetina et al., 2005). In this study, we 
have investigated the activation of the Hh pathway, by focusing on the expression of the 
transcriptional activator of the Hh signal (Gli-1). We have demonstrated that, by stimulating the 
pathway in healthy and HGA-treated chondrocytes with the agonist SAG, introduced a greater 
induction of Gli-1 expression in the presence of HGA. To explain these results, we can hypothesize 
that the activity of the agonist SAG synergizes with HGA to activate Smo, although this mechanism 
has not been clarified yet. 
Several recent studies have highlighted the potential efficacy of hedgehog antagonists in the 
prevention of cartilage degradation in OA and RA (Lin et al., 2009; Ruiz-Heiland et al., 2010; Zhou 
et al., 2014). On the basis of this previous evidence, antagonists of Smo have been tested in this 
work to evaluate their potential inhibitory effect of Hh pathway. In addition to the natural 
teratogenic compound cyclopamine, another inhibitor of Smo signalling has been used, vismodegib, 
which is the first antagonist of Hedgehog pathway approved by FDA for treating BBC (Basal Cell 
Carcinoma) (Amakye et al., 2013). Moreover, two new Smo inhibitors, MRT89 and MRT61, 
recently developed in our laboratories, have been tested for the same experiments. We have 
demonstrated that in primary human chondrocytes, the reduction in cilia length caused by treatment 
with HGA was restored to that in healthy cells by Smo antagonists. Cilia elongation induced by 
Smo antagonists has not previously been reported and the mechanism for this is unknown. Smo 
antagonists also reduced Gli-1 expression in a concentration-dependent manner.  
The possibility to antagonize Hedgehog signalling in AKU is an important discovery, which 
suggest employing this pathway as a potential therapeutic target for reducing cartilage degradation 
processes that characterize the disease. AKU is a genetic disease, caused by mutations of the 
enzyme responsible for the metabolism of HGA and in most cases, the symptoms appear in 
adulthood, therefore targeting a cellular pathway fundamental for development processes would be 
useful at the later stages of the disease as a symptomatic approach to prevent further cartilage 
degradation caused by HGA. 
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Figure 1. HGA-induced pigmentation by phase contrast imaging. (A) Primary human healthy 
chondrocytes observed at the optic microscope resulted transparent; (B) AKU chondrocytes 
presented pigment deposition and, similarly, healthy chondrocytes cultured in presence of HGA at 
66 μM showed the same phenotypic features (C). Coloured boxes represent pigmented cells, 
enlarged in order to show pigment deposition, mainly around nuclei. Objective magnification: 10x.  
Figure 2. Primary cilia and Hh signalling characterization in primary human chondrocytes. (A) (B) 
Confocal imaging and statistical analysis of cilia lengths after immunostaining with anti acetylated 
α-tubulin antibody. Scale bar: 20 μm. White boxes indicate representative cells, scale bar: 10 μm. 
Statistical analysis were performed by 2-way ANOVA with Tukey’s multiple comparisons tests. 
(C) Western blot analysis of Gli-1 expression in response to the agonist SAG (100 nM). Statistics 
were performed by one-way ANOVA test. In all cases, statistically significant differences relative 
to untreated control were indicated. 
Figure 3. MTT assay. Cell viability, expressed in percentage relative to control, was not affected 
neither by treatment with HGA at 66 µM, nor by treatment with cyclopamine, vismodegib, MRT89 
and MRT61 at 1 nM, 10 nM and 100 nM. 
Figure 4. Confocal imaging of primary cilia of chondrocytes treated with Smo antagonists and cilia 
length measurements. Images obtained at the confocal microscope show that HGA-treated 
chondrocytes have shorter cilia. However cilia length was restored to that seen in healthy cells by 
treatment with cyclopamine, vismodegib, MRT89 and MRT61 at 1, 10 and 100 nM. Data 
statistically analysed by 2-way ANOVA with Tukey’s multiple comparisons tests (p-values 
calculated in comparison with CTR or +HGA samples).  
Figure 5. Gli-1 expression analysis after treatment with Smo antagonists. (A) Immuno-reactive 
bands resulting from western blot analysis. (B) Quantification of Gli-1 expression in protein lysates 
obtained from primary human chondrocytes cultures in presence of HGA + SAG (100 nM) + Smo 
antagonist (1 nM, 10 nM, 100 nM). Protein expression significantly decreased in a concentration-
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Table 1 Primary cilia lengths and percentages of increase in respect to HGA-treated chondrocytes, 





Cilia length mean ± 
S.E.M. (μm) 




 10  
100  
4 ± 1.2 
4.1 ± 1 








3.8 ± 0.8 
3.9 ± 0.9 








3.1 ± 0.9 
3.1 ± 0.8 








2.9 ± 0.8 
3 ± 0.9 
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